NCT02188693

Gemcitabine as a Single Agent in the Maintenance Chemotherapy of Patients With Metastatic Breast Cancer

Maintenance Versus Observation With 6 Cycles of Gemcitabine Plus Taxol Sequential Gemcitabine Single Agent in Patients With Metastatic Breast Cancer

• Status: Unknown
• Phase: —
• Study type: Observational
• Enrollment: 267 (estimated)
• Sponsor: Xijing Hospital · Academic / Other
• Sex: Female
• Age: 18 Years – 70 Years
• Healthy volunteers: Not accepted

Summary

The primary purpose of our study is to evaluate whether gemcitabine as a single agent is superior to observation in improving progression-free survival (PFS) in patients with metastatic breast cancer (MBC) who achieved disease control with an initial six cycles of PG as their first-line treatment

Conditions

• Stage IIIB, IV, Recurrent, and Metastatic Breast Cancer
• Gemcitabine
• Maintenance Chemotherapy

Timeline

• Start date: 2014-07-01
• Primary completion: 2017-07-01
• Completion: 2017-12-01
• First posted: 2014-07-14
• Last updated: 2014-07-14

Locations

1 site across 1 country: China